info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Rare Neurological Disease Treatment Market Research Report By Disease Type (Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Huntington's Disease, Neuromuscular Diseases, Epilepsy), By Treatment Modality (Pharmaceuticals, Gene Therapy, Cell Therapy, Immunotherapy, Medical Devices), By Patient Population (Adults, Pediatrics), By Route of Administration (Oral, Injectable, Topical, Intravenous), By Market Status (Approved, Investigational, Development) and By Regional (North America, Europe, South America, Asia Pacific, Middle Eas


ID: MRFR/HC/26000-HCR | 100 Pages | Author: Rahul Gotadki| October 2024

Global Rare Neurological Disease Treatment Market Overview


As per MRFR analysis, the Rare Neurological Disease Treatment Market Size was estimated at 9.07 (USD Billion) in 2022.


 The Rare Neurological Disease Treatment Market Industry is expected to grow from 9.63(USD Billion) in 2023 to 16.4 (USD Billion) by 2032. The Rare Neurological Disease Treatment Market CAGR (growth rate) is expected to be around 6.09% during the forecast period (2024 - 2032).


Key Rare Neurological Disease Treatment Market Trends Highlighted


Advancements in gene therapy, including the development of gene editing tools like CRISPR-Cas9, hold promising prospects for treating rare neurological diseases at the genetic level. The rise of precision medicine enables tailored treatments based on individual genetic makeup, leading to improved patient outcomes. Furthermore, increased government funding and research collaborations are fostering a conducive environment for innovation and drug development. The growing prevalence of rare neurological diseases, coupled with unmet medical needs, presents significant opportunities for pharmaceutical companies to develop novel therapies and capture market share.


Rare Neurological Disease Treatment Market Overview


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Rare Neurological Disease Treatment Market Drivers


Increasing Prevalence of Rare Neurological Diseases


The increasing prevalence of rare neurological diseases is a key driver of the growth of the Rare Neurological Disease Treatment Market Industry. Rare neurological diseases are a group of disorders that affect the nervous system and are characterized by their low prevalence. Most rare neurological diseases are of unknown cause but are thought to result from a combination of genetic and environmental factors. There are a number of reasons for the increasing prevalence of rare neurological diseases worldwide: Better medical technology: With the growing use of advanced medical technology, new, more sensitive, and more accurate diagnostic tests for rare neurological diseases have been developed, leading to an increase in the number of people being diagnosed with these conditions.


 Growing awareness: There is a growing awareness of rare neurological diseases among the general public and medical professionals due to a number of ongoing activities such as The media coverage of rare neurological diseases, The activities of rare neurological disease patient advocacy groups, The efforts of the government to increase awareness of rare neurological diseases. The increasing prevalence of rare neurological diseases is a serious challenge for healthcare systems around the world.


Rare neurological diseases can be difficult to diagnose and treat and can have a major impact on the quality of life of both patients and their families. The increasing prevalence of rare neurological diseases is thus a serious concern. The growth of the Rare Neurological Disease Treatment Market Industry is, on the other hand, a positive development as it implies that there is more and more of a commitment to improving the lives of those who are affected by rare neurological diseases.


Rising Demand for Personalized Medicine


Another factor responsible for the expansion of the Rare Neurological Disease Treatment Market Industry is the increasing demand for personalized medicine. Personalized medicine is the best way to provide healthcare by taking into account the characteristics of every patient. These peculiarities include the genetic spectrum, surrounding environment, particularities of lifestyle, etc. Therefore, personalized medicine can be applied to develop effective treatments for rare neurological diseases.


There are several reasons for the increasing demand for personalized medicine: The high cost of treatment. The number of expenses for providing proper healthcare is increasing every year. Nevertheless, the utilization and effectiveness of treatment prescribed for a particular group of patients remain low. The targeted treatment can be provided by personalized medicine, so it is appropriate to choose the best way to assist an individual patient that helps reduce the overall cost of anti-disease measures.


 Increasing numbers of chronic diseases. It is evident that nowadays, people suffer from more chronic diseases than ever. There are many reasons for such a tendency, such as the rapidly aging global population, unhealthy lifestyles, effective ways of consequence elimination, etc. Modern people need to pay much attention to their physical health, and the increased personalized medicine management phenomenon is evident, as these services help increase the quality of life for people with particular chronic maladies.


Government Support for Rare Disease Research and Development


Government support for rare disease research and development is a key driver of the growth of the Rare Neurological Disease Treatment Market Industry. Governments around the world are recognizing the importance of rare diseases and are providing funding for research and development of new treatments. This support is essential for the development of new and innovative treatments for rare neurological diseases. There are a number of factors driving government support for rare disease research and development, including: The high cost of rare diseases: Rare diseases can be very expensive to treat.


This is due to a number of factors, including The high cost of developing new drugs and treatments and the small number of patients with each rare disease. The need for specialized care. Government support can help to reduce the cost of rare diseases by funding research and development of new treatments. The impact of rare diseases on patients and families: Rare diseases can have a significant impact on the quality of life of patients and their families.


This is due to a number of factors, including The physical and emotional symptoms of rare diseases, The financial burden of rare diseases The social stigma associated with rare diseases. Government support can help to improve the quality of life of patients and families by funding research and development of new treatments.


Rare Neurological Disease Treatment Market Segment Insights:


Rare Neurological Disease Treatment Market Disease Type Insights


The Rare Neurological Disease Treatment Market is segmented by disease type into Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Huntington's Disease, Neuromuscular Diseases and Epilepsy. Among these, Alzheimer's Disease is estimated to hold the largest market share in 2023, accounting for over 50% of the global market revenue. The high prevalence of Alzheimer's Disease, coupled with the lack of effective treatment options, is driving the growth of this segment. Parkinson's Disease is another major segment with a significant market share.


The increasing incidence of Parkinson's Disease and the availability of various treatment options are contributing to the growth of this segment. Multiple Sclerosis, Huntington's Disease, Neuromuscular Diseases, and Epilepsy are other key segments in the Rare Neurological Disease Treatment Market, with each segment offering growth opportunities for market players. The increasing focus on developing novel therapies and the growing awareness of rare neurological diseases are expected to drive the growth of these segments in the coming years.


Overall, market segmentation provides insights into the specific needs of patients with different rare neurological diseases, enabling market players to develop targeted strategies and products to meet the unmet medical needs of this patient population.


Rare Neurological Disease Treatment Market Disease Type Insights


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Rare Neurological Disease Treatment Market Treatment Modality Insights


The Rare Neurological Disease Treatment Market segmentation by Treatment Modality comprises Pharmaceuticals, Gene Therapy, Cell Therapy, Immunotherapy and Medical Devices. Among these, Pharmaceuticals held the largest market share in 2023 and is projected to continue its dominance during the forecast period. The growth of this segment can be attributed to the availability of a wide range of FDA-approved drugs for the treatment of rare neurological diseases. Gene Therapy and Cell Therapy are emerging treatment modalities that have shown promising results in clinical trials and are expected to gain significant market share in the coming years.


Immunotherapy is another promising treatment approach that is being investigated for the treatment of rare neurological diseases. Medical Devices play a crucial role in the diagnosis and monitoring of rare neurological diseases, contributing to the growth of this segment.


Rare Neurological Disease Treatment Market Patient Population Insights


The Rare Neurological Disease Treatment Market is segmented based on patient population into adults and pediatrics. The adult segment is expected to account for a larger share of the market in 2023, owing to the higher prevalence of rare neurological diseases in this population. However, the pediatrics segment is expected to witness a higher growth rate during the forecast period due to increasing awareness and diagnosis of rare neurological diseases in children. In 2023, the adult segment is expected to be valued at USD 6.43 billion, while the pediatrics segment is expected to be valued at USD 3.2 billion.


By 2032, the adult segment is projected to reach USD 10.6 billion, while the pediatrics segment is expected to reach USD 5.8 billion. The growth of the pediatrics segment is attributed to the increasing number of research and development initiatives focused on developing new and innovative treatments for rare neurological diseases in children.


Rare Neurological Disease Treatment Market Route of Administration Insights


The Route of Administration segment of the Rare Neurological Disease Treatment Market plays a crucial role in determining the delivery and efficacy of treatments. Oral administration remains the most preferred route, accounting for a significant share of the market in 2023. Its convenience and ease of use make it suitable for chronic conditions requiring long-term therapy. Injectable therapies, including subcutaneous and intravenous injections, are gaining traction due to their ability to deliver precise doses directly to the target site.


Intravenous administration offers a rapid onset of action and is used for severe or life-threatening conditions. Topical treatments, applied directly to the affected area, are gaining popularity for localized neurological disorders. The Rare Neurological Disease Treatment Market is expected to witness a growing preference for injectable and intravenous routes of administration in the coming years, driven by the development of novel therapies and targeted drug delivery systems.


Rare Neurological Disease Treatment Market Market Status Insights


The Rare Neurological Disease Treatment Market is segmented based on market status into approved, investigational and development. The approved segment accounted for the largest share of the market in 2023 and is expected to continue to dominate the market during the forecast period. This is due to the increasing number of approvals for new drugs and biologics for rare neurological diseases. The investigational segment is expected to experience significant growth during the forecast period, owing to the increasing number of clinical trials for new drugs and biologics for rare neurological diseases.


The development segment is expected to have a moderate growth rate during the forecast period due to the time-consuming and expensive process of developing new drugs and biologics. This growth is attributed to the increasing prevalence of rare neurological diseases, the rising demand for effective treatments, and the growing number of government initiatives to support the development and commercialization of rare disease therapies.


Rare Neurological Disease Treatment Market Regional Insights


The Rare Neurological Disease Treatment Market is segmented regionally into North America, Europe, APAC, South America and MEA. North America is expected to hold the largest market share due to the high prevalence of rare neurological diseases, strong healthcare infrastructure, and government support for research and development. Europe is expected to follow North America in terms of market size, driven by factors such as advances in healthcare technology and a large patient population. APAC is expected to witness significant growth due to the rising disposable income and increasing awareness of rare neurological diseases.


South America and MEA are expected to grow steadily, driven by improving healthcare infrastructure and increasing government initiatives.


Rare Neurological Disease Treatment Market Regional Insights


Source: Primary Research, Secondary Research, MRFR Database and Analyst Review


Rare Neurological Disease Treatment Market Key Players And Competitive Insights:


The Rare Neurological Disease Treatment Market is highly competitive, with major companies such as Biogen and Roche gaining a competitive advantage through significant investments in research and development. In addition, companies in this market are continuing to pursue this advantage by constructing new product launches at an unprecedented rate. The leading players in the Rare Neurological Disease Treatment Market are also acquiring worldwide expansion by acquiring smaller competitors and partnering with companies in other geographies. The Rare Neurological Disease Treatment Market is characterized by both digestible incumbent and completely new players, each of whom has their own strengths and weaknesses. Over the next few years, the competitive Rare Neurological Disease Treatment Market is likely to continue, with newcomers entering the industry and technological advancements reshaping the market.


Biogen is one of the leading Rare Neurological Disease Treatment Market players worldwide. Biogen is a worldwide pioneer in the research and commercialization of neurological disease therapies, which include a number of key life medicines for multiple sclerosis, Alzheimer’s disease, and spinal muscle atrophy. Due to the company’s commitment to innovation, it has developed numerous groundbreaking therapies, including aducanumab, the FDA’s first approved therapy for Alzheimer’s disease. Its strong drug pipeline has allowed Biogen to market new medicinal items and gain a foothold in the Rare Neurological Disease Treatment Market.


Roche is a prominent player in the Rare Neurological Disease Treatment Market. The company is renowned for its clinical and biological prowess and provides medicinal treatments for patients all over the globe. Roche’s products include medicines for a broad variety of neurological illnesses such as multiple sclerosis, Parkinson’s disease, and Huntington’s disease. Furthermore, the firm’s dedication to research and development has resulted in the launch of game-changing therapies such as ocrelizumab for the treatment of various types of multiple sclerosis and risdiplam, an effective therapeutic therapy for spinal muscular atrophy. In addition, the commercial of the drug in a variety of geographic regions, as well as the patient-centric business strategy of the firm allows Roche to maintain its competitive edge in the Rare Neurological Disease Treatment Market.


Key Companies in the Rare Neurological Disease Treatment Market Include:




  • Eli Lilly and Company




  • AstraZeneca




  • Roche




  • Gilead Sciences




  • Biogen




  • Sanofi




  • BristolMyers Squibb




  • Pfizer




  • Actelion Pharmaceuticals




  • Jazz Pharmaceuticals




  • Celgene




  • Novartis




  • AbbVie




  • Merck Co




  • Teva Pharmaceutical Industries




Rare Neurological Disease Treatment Market Industry Developments


The Rare Neurological Disease Treatment Market is projected to reach USD 16.4 billion by 2032, exhibiting a CAGR of 6.09% during the forecast period (2024-2032). The market growth is attributed to increasing prevalence of rare neurological diseases, rising demand for novel therapies, and supportive government initiatives.


Recent developments in the market include:


 In 2023, Biogen received FDA approval for Aduhelm, the first Alzheimer's drug approved in nearly two decades.


 In 2022, Roche acquired Prothena Biosciences for $5.3 billion, gaining access to their pipeline of treatments for neurodegenerative diseases.


 Several clinical trials are underway for gene therapies and other innovative treatments for rare neurological diseases, offering hope for patients and their families.


Rare Neurological Disease Treatment Market Segmentation Insights




  • Rare Neurological Disease Treatment Market Disease Type Outlook




    • Alzheimer's Disease




    • Parkinson's Disease




    • Multiple Sclerosis




    • Huntington's Disease




    • Neuromuscular Diseases




    • Epilepsy






 




  • Rare Neurological Disease Treatment Market Treatment Modality Outlook




    • Pharmaceuticals




    • Gene Therapy




    • Cell Therapy




    • Immunotherapy




    • Medical Devices






 




  • Rare Neurological Disease Treatment Market Patient Population Outlook




    • Adults




    • Pediatrics






 




  • Rare Neurological Disease Treatment Market Route of Administration Outlook




    • Oral




    • Injectable




    • Topical




    • Intravenous






 




  • Rare Neurological Disease Treatment Market Market Status Outlook




    • Approved




    • Investigational




    • Development






 




  • Rare Neurological Disease Treatment Market Regional Outlook




    • North America




    • Europe




    • South America




    • Asia Pacific




    • Middle East and Africa





Report Attribute/Metric Details
Market Size 2022 9.07(USD Billion)
Market Size 2023 9.63(USD Billion)
Market Size 2032 16.4(USD Billion)
Compound Annual Growth Rate (CAGR) 6.09% (2024 - 2032)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Base Year 2023
Market Forecast Period 2024 - 2032
Historical Data 2019 - 2023
Market Forecast Units USD Billion
Key Companies Profiled Eli Lilly and Company, AstraZeneca, Roche, Gilead Sciences, Biogen, Sanofi, BristolMyers Squibb, Pfizer, Actelion Pharmaceuticals, Jazz Pharmaceuticals, Celgene, Novartis, AbbVie, Merck Co, Teva Pharmaceutical Industries
Segments Covered Disease Type, Treatment Modality, Patient Population, Route of Administration, Market Status, Regional
Key Market Opportunities Orphan drug designation incentives Rising prevalence of rare neurological diseases Technological advancements in gene therapy and precision medicine Strategic collaborations and partnerships Government initiatives for research and development
Key Market Dynamics The rising prevalence of rare neurological diseases is increasing government funding for research technological advancements in gene therapy, growing demand for personalized medicine and expanding pipeline of novel therapies.
Countries Covered North America, Europe, APAC, South America, MEA


Frequently Asked Questions (FAQ) :

The Rare Neurological Disease Treatment Market was valued at USD 9.63 Billion in 2023 and is projected to reach USD 16.4 Billion by 2032, exhibiting a CAGR of 6.09%.

The rising prevalence of rare neurological disorders, increasing government initiatives and funding for research and development, and growing awareness about the availability of treatments are primarily driving the market growth.

North America is expected to dominate the market due to high healthcare expenditure, the presence of leading pharmaceutical companies, and well-established healthcare infrastructure.

The major application segments include Alzheimer's disease, Parkinson's disease, multiple sclerosis, Huntington's disease, and other rare neurological disorders.

Key competitors include Biogen, Roche, Novartis, Pfizer, and Merck.

The high cost of treatment, lack of awareness, and limited access to specialized healthcare facilities pose challenges to market growth.

Advancements in gene therapy, personalized medicine, and digital health technologies present significant growth opportunities.

The market is projected to exhibit a CAGR of 6.09% during the forecast period 2023-2032.

Increasing adoption of precision medicine, growing emphasis on early diagnosis, and rising investments in RD are key trends shaping the market.

Government regulations, such as the Orphan Drug Act, play a crucial role in encouraging research and development of treatments for rare neurological diseases.

Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.